Frank D. Lee insider trades: Bausch Health Companies (BHC) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Frank reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | BHC | ↓ Sell10b5-1 | 24,456 | $5.43 | $133K | Direct | May 20, 2026 (1d) |
| Aug 21, 2025 | BHC | ↓ Sell | 15,912 | $7.66 | $122K | Direct | Aug 22, 2025 (1d) |
| Aug 12, 2024 | PCRX | ↑ Buy | 8,264 | $12.10 | $100K | Direct | Aug 13, 2024 (1d) |
| Feb 23, 2022 | FMTX | ↓ Sell | 17,981 | $9.78 | $176K | Direct | Feb 25, 2022 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BHC insiders
Open-market trades in the last 12 months
About Frank D. Lee's insider trades
Frank D. Lee is a director at Bausch Health Companies (BHC). Since Feb 23, 2022, Frank has reported 1 open-market purchase worth $100K and 3 sales worth $430K on SEC Form 4. In the last 12 months: 1 sale ($133K).
1 sale (31% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (13 filings), shares withheld for taxes (3 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BHC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.